Lipocine (LPCN) Research & Development (2012 - 2025)
Lipocine's (LPCN) quarterly Research & Development came in at $2.7 million in Q3 2025, up 70.81% YoY from $1.6 million in Q3 2024, and up 26.72% on a QoQ basis from $2.1 million in Q2 2025.
Lipocine (LPCN) Research & Development (2012 - 2025) Analysis & Trends
Lipocine (LPCN) has 14 years of Research & Development data on file, last reported at $2.7 million in Q3 2025.
- Quarterly Research & Development rose 70.81% year-over-year to $2.7 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $7.0 million (down 12.26% YoY) and the FY2024 annual result came in at $7.4 million, down 27.75% from the prior year.
- Research & Development advanced to $2.7 million in Q3 2025, from $2.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $3.1 million in Q1 2023 to a low of $1.1 million in Q1 2025.
- A 5-year average of $2.1 million and a median of $2.1 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 97.86% — and 2025, when it slumped 62.34%.
- Tracing LPCN's Research & Development over 5 years: stood at $2.3 million in 2021, then fell by 25.88% to $1.7 million in 2022, then increased by 0.27% to $1.7 million in 2023, then sank by 35.95% to $1.1 million in 2024, then jumped by 152.39% to $2.7 million in 2025.
- The last three Research & Development figures came in at $2.7 million (Q3 2025), $2.1 million (Q2 2025), and $1.1 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Lipocine | 11.34 Mn | -12.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.71 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 1.07 Mn |
| Sep 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.87 Mn |
| Mar 31, 2024 | 2.82 Mn |
| Dec 31, 2023 | 1.67 Mn |
| Sep 30, 2023 | 2.88 Mn |
| Jun 30, 2023 | 2.52 Mn |
| Mar 31, 2023 | 3.11 Mn |
| Dec 31, 2022 | 1.67 Mn |
| Sep 30, 2022 | 2.10 Mn |
| Jun 30, 2022 | 2.90 Mn |
| Mar 31, 2022 | 1.89 Mn |
| Dec 31, 2021 | 2.25 Mn |
| Sep 30, 2021 | 2.37 Mn |
| Jun 30, 2021 | 1.46 Mn |
| Mar 31, 2021 | 1.58 Mn |
| Dec 31, 2020 | 2.48 Mn |